{
    "clinical_study": {
        "@rank": "146485", 
        "arm_group": {
            "arm_group_label": "Ramelteon 8 mg Tablets"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to examine the safety and efficacy of long-term use of\n      ramelteon tablets (Rozerem 8 mg Tablets) in patients with difficulty falling asleep\n      associated with insomnia in daily medical practice."
        }, 
        "brief_title": "Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> \u2212 Transitional Survey From the Preceding Drug-use Survey \u2212", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Insomnia", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "detailed_description": {
            "textblock": "This survey was designed to examine the safety and efficacy of long-term use of ramelteon\n      tablets (Rozerem 8 mg Tablets) in patients with difficulty falling asleep associated with\n      insomnia in daily medical practice.\n\n      The usual dosage for adults is 8 mg of ramelteon administered orally once daily at bedtime."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with difficulty falling asleep associated with insomnia who have completed a\n             4-week follow-up in the preceding drug use surveillance and are able to receive\n             continuous administration of Rozerem Tablets\n\n        Exclusion Criteria:\n\n          -  Patients with contraindications to Rozerem Tablets\n\n               1. Patients with previous history of hypersensitivity to ingredients in Rozerem\n                  Tablets\n\n               2. Patients with severe liver dysfunction\n\n               3. Patients taking fluvoxamine maleate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Insomnia"
            }
        }, 
        "enrollment": {
            "#text": "236", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153086", 
            "org_study_id": "293-011"
        }, 
        "intervention": {
            "arm_group_label": "Ramelteon 8 mg Tablets", 
            "description": "Ramelteon tablets 8 mg", 
            "intervention_name": "Ramelteon", 
            "intervention_type": "Drug", 
            "other_name": "Rozerem 8 mg Tablets"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Rozerem 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Associated With Sleep-onset Difficulty > \u2212 Transitional Survey From the Preceding Drug-use Survey \u2212", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of ramelteon whether or not it was considered related to treatment. Among these, events that are considered as having a causal relationship with ramelteon are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 6 months (for 1 year in patients for whom follow-up can be performed)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153086"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes from baseline in sleep status from the start of the surveillance will be tabulated and assessed.", 
                "measure": "Sleep status (sleep latency, total sleep time, and number of awakenings)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 6 months of treatment (for 1 year in patients for whom follow-up can be performed)"
            }, 
            {
                "description": "Results of surveys using the PGI questionnaire will be scored, and scores for 7 items (sleep onset, sleep duration, sleep quality, morning awakening, remaining tiredness in the morning, daytime somnolence, and daytime physical condition/function) will be tabulated and assessed.", 
                "measure": "Change from baseline in patient global impression (PGI) score", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 6 months of treatment (for 1 year in patients for whom follow-up can be performed)"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}